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it is unlikely given the total lack of vellus or terminal
hair growth by 3 months. Based on the current find-
ings, we would not recommend the use of this medi-
cation for the treatment of patients with alopecia areata
without additional evidence of therapeutic benefit.
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Monochromatic excimer light (308 nm) in
patch-stage IA mycosis fungoides
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Recently, numerous studies have been reported concerning the treatment of early-stage mycosis fungoides (MF)
with narrowband (311-nm) UVB, claiming a beneficial response. We have used for the first time a 308-nm
monochromatic excimer light, a new kind of xenon-chloride lamp, in the treatment of patch stage IA MF. We
treated 7 patch lesions in 4 patients with unequivocal clinicopathologic diagnosis of MF. All lesions achieved
clinical and histologic complete remission. The number of weekly sessions varied from 4 to 11 (mean 6.5;
median 5.5). The total UVB 308-nm irradiation dose ranged from 5 to 9.3 J/cm2 (mean 7.1 J/cm2; median 7
J/cm2). All lesions remained in stable complete remission after a follow-up of 3 to 28 months. No remarkable side
effects were reported. Our preliminary results suggest that monochromatic excimer light phototherapy is a
possibly very useful treatment modality in patch stage IA MF. (J Am Acad Dermatol 2004;50:943-5.)
T he treatment of stage I mycosis fungoides(MF), the prototype of cutaneous T-cell lym-phoma, consists of topical steroids, UVB
phototherapy, photochemotherapy (psoralen-UVA),
topical chemotherapy, or total skin electron-beam
irradiation.1 Good results obtained with broadband
UVB phototherapy (280- to 320-nm wavelength) in
the treatment of stage I MF (especially in its patch
phase) have been reported previously.2,3 Recently,
several studies have been published concerning the
treatment of stage I MF with narrowband (311-nm)
UVB phototherapy, claiming a beneficial response.
4-7
Recently, it has been demonstrated that the light
produced by xenon-chloride excimer, generated by
sophisticated devices, with monochromatic light
emission at 308 nm (monochromatic excimer light
[MEL]) quickly and selectively induces the clearance
From the Department of Dermatological Sciencesa and, Physical
Therapy Unit,b University of Florence Medical School.
Supported by the Ente Cassa di Risparmio di Firenze.
Conflicts of interest: None identified.
Reprint requests: Nicola Pimpinelli, MD, PhD, Department of
Dermatological Sciences, University of Florence, Via degli Alfani,
37, 50121 Florence, Italy. E-mail: pimpi@unifi.it.
0190-9622/$30.00
© 2004 by the American Academy of Dermatology, Inc.
doi:10.1016/j.jaad.2004.01.047
Brief reports 943J AM ACAD DERMATOL
VOLUME 50, NUMBER 6
of psoriatic lesions with an excellent benefit/risk
profile.8
We report herein the preliminary results of our
pilot study with MEL phototherapy in the treatment
of patch stage IA MF. This specific condition, char-
acterized by limited extension of the disease and
thickness of the lesions, was considered ideal to
check safely the possible benefits of this new treat-
ment modality.
PATIENTS AND METHODS
Patients
Four patients (2 men and 2 women; age range
35-78 years) with unequivocal clinicopathologic di-
agnoses of patch stage IA MF were recruited. Of the
4 patients, one had just been given a diagnosis, and
3 were on first relapse after psoralen-UVA therapy,
which had been discontinued at least 6 months be-
fore starting MEL phototherapy. After informed con-
sent, patients were required to discontinue topical
steroid treatment for 4 weeks.
Methods
The 308-nm XeCl MEL (Excilite-Deka, Florence,
Italy) has a power density of 50 mW/cm2 at the
distance of 15 cm from source, with a maximum
irradiating area of 512 cm2. Before treatment, all
patients were phototested to determine the minimal
erythema dose of 308-nm UVB by exposing a small
area of uninvolved skin on the buttocks to a geo-
metric dose range between 150 and 500 mJ/cm2 for
3 to 10 seconds. After protecting nonaffected skin
with papers or a total-block sunscreen cream, each
MF lesion was irradiated. The first treatment session
started from 2 to 3 minimal erythema dose
(range: 0.5-1 J/cm2) and increased by 150 to 500
mJ/cm2 (3-10 seconds) during subsequent sessions.
Each patient underwent a variable number of treat-
ment sessions (between 3 and 8). The treatment
sessions were performed weekly. Treatment was
stopped on clinical complete remission. Biopsy
specimens were taken before and after MEL photo-
therapy. Clinical evaluation was performed weekly
for 3 months, then monthly. No additional treatment
was performed during the study period, except for
an emollient cream.
RESULTS
All 7 lesions of 4 patients with patch stage I MF
achieved both clinical (Figs 1 and 2) and histologic
complete remission. The number of weekly sessions
varied from 4 to 11 (mean 6.5; median 5.5). The total
UVB 308-nm irradiation dose ranged from 5 to 9.3
J/cm2 (mean 7.1 J/cm2; median 7 J/cm2). All patients
underwent complete remission, which remained sta-
ble during follow-up of 3 to 28 months. In particular,
all treated lesions remain cleared. During follow-up,
one patient experienced a relapse in a different skin
site, which was successfully treated with the same
protocol. The most common side effects were min-
imal erythema and itch, eventuating into mild and
transient hyperpigmentation.
DISCUSSION
Recently, two studies concerning the treatment of
stage I MF with narrowband (311-nm) UVB have
been published. In one of the above studies, com-
plete remission was achieved in 17 of 21 patients
(81%), with a mean relapse-free interval of 24.5
months (range: 2-66 months).7 In the other study,
complete remission was achieved in 13 of 24 pa-
tients (54.2%), with a mean time to relapse of 12.5
weeks.6
In our pilot study, MEL was used for the first time
in the treatment of patch stage IA MF. We treated 7
lesions in 4 patients with patch stage IA MF, with
clinicopathologic complete remission in all cases.
Compared with traditional phototherapy, MEL can
Fig 1. A 38-year-old woman with patch stage IA mycosis
fungoides. Large patch of right buttock before treatment
with monochromatic excimer light 308-nm phototherapy.
Fig 2. Same patient as in Fig 1 after treatment with mono-
chromatic excimer light 308-nm phototherapy (5 ses-
sions).
944 Brief reports J AM ACAD DERMATOL
JUNE 2004
selectively treat single lesions, sparing clinically
nonaffected skin and achieving clinical remission
very quickly. Compared with UVB 311-nm therapy,
usually administered 2 to 3 times a week on non-
consecutive days, MEL treatment sessions were per-
formed weekly, with very good patient compliance.
The mechanisms of action of UVB therapy in MF
are still unknown. In vitro experiments show that
UVB decreased the allo-activating and antigen-pre-
senting capacity of Langerhans cells and increased
IL-2 and IL-6 production by human keratinocytes.9,10
Recently, it has been indicated that psoriatic skin
after MEL therapy is associated with significant T-cell
depletion and alteration of apoptosis-related mole-
cules, accompanied by a decreased proliferation in-
dex and clinical remission.11 In the specific context
of MF, narrowband and monochromatic UVB light
could functionally suppress the neoplastic, clonal
T-cell population in the skin, and act as up-regulator
of immune modulation.
Our preliminary results suggest that MEL photo-
therapy is a possibly very useful treatment modality
in patch stage IA MF. It remains to be elucidated as
to what is the best protocol in terms of ratio between
risks (side effects) and benefits (rapidity and stability
of remissions). A larger, multicenter experience and
controlled clinical trials are needed to check the
possible role of MEL phototherapy as first-line treat-
ment of stage I MF compared with narrowband UVB
and, especially, psoralen-UVA therapy.
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